Symbols

ALDX

Aldeyra Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 0

Ample Liquidity

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ALDX

Aldeyra Therapeutics, Inc.

A biotechnology company developing novel therapies for immune-mediated diseases

Industry

Pharmaceutical

Established Date

08/13/2004

Listing Date

05/02/2014

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.aldeyra.com

Security Type

Common stock

Office address

131 Hartwell Avenue, Suite 320, Lexington, MA 02421

Business

Introduction

Aldeyra Therapeutics, Inc., was incorporated in Delaware on August 13, 2004. The company is a clinical-stage biotechnology company dedicated to the discovery and development of innovative therapies designed to treat immune-mediated diseases. Its approach focuses on regulating the protein system, and late-stage drug candidates include reproxalap for dry eye disease and allergic conjunctivitis, and ADX-2191 for retinal diseases.

Company Financials

EPS

ALDX has released its 2025 Q3 earnings. EPS was reported at -0.13, versus the expected -0.25, beating expectations. The chart below visualizes how ALDX has performed over recent quarters, highlighting trends in earnings surprises.